Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570308 · ClinicalTrials.gov registry record · Phase 1
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
A Phase 1 study, sponsored by Immunocore.
- Completed
- Registry status
- Phase 1
- Development phase
- 146
- Enrollment target
NCT02570308 is a Phase 1 study that has completed, run by Immunocore. The registered enrollment target is 146 participants.
The verdict
NCT02570308, a Phase 1 study, has completed, sponsored by Immunocore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 146 participants
- Enrollment target
Study Summary
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM). According to this regimen, all participants in the trial received 2 weekly doses of IMCgp100 at a dose level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose escalation commenced at the third weekly dose at C1D15. The Phase I testing of the intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter.
Interventions
- DRUG IMCgp100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570308
The ClinicalTrials.gov registry entry for NCT02570308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 is the first listed.
NCT02570308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570308 about?
NCT02570308 is a clinical study titled "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma". IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM). According to this regimen, all participants in the trial received 2 weekly doses of IMCgp100 at a dose level below the identifi...
What is the current status of trial NCT02570308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2016-02-29. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT02570308?
The interventions under investigation include: IMCgp100 (DRUG).
Who is sponsoring clinical trial NCT02570308?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.